Kyle Blair, DO
Retina Specialist · Des Plaines, ILNPI 1699121194
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,457 of the $4,963 with a category attached, or 69.7%. 7 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 35.6% of the total. Reporting peaked in 2022 at $3,047 and has fallen 95.2% since, to $147 in 2025.
Across 45 payments — averaging $110.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Bausch & Lomb Americas Inc.$2K
- Alcon$1K
- Regeneron Healthcare Solutions, Inc.$135
- Astellas Pharma US Inc$30
- Apellis Pharmaceuticals, Inc.$30
- plus $28 from 1 others
What the payments were for
- Travel & lodging$3,45770%
- Food & beverage$1,50630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $1,769 |
| Bausch & Lomb Americas Inc. | 16 | $1,675 |
| Alcon | 4 | $1,295 |
| Regeneron Healthcare Solutions, Inc. | 2 | $135 |
| Astellas Pharma US Inc | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$2,572
- Crystalens Accommodating IOL (AT-52AO)$1,326
- Trulign IOL$1,326
- Akreos AO IOL$1,326
- enVista MX60 IOL$1,326
- OPHTHALMIC INSTRUMENTS$1,246
- EYLEA$100
How this compares
$4,963 in reported general payments places this provider in the 60th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 105 | $3,255 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 63 | $1,080 |
| Ketorolac Tromethamine | 56 | $693 |
| Brimonidine Tartrate | 49 | $372 |
| Latanoprost | 28 | $224 |
| Timolol Maleate | 28 | $151 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Des Plaines
- Bryan KimDes Plaines$8K
- Saira KhannaDes Plaines$5K
- Anand GopalDes Plaines$2K
- George WyhinnyDes Plaines$2K
- Enrique Garcia-ValenzuelaDes Plaines$2K
- Daniel AlterDes Plaines$2K
- Michael BlairDes Plaines$927
- Robert GaroonDes Plaines$515
- Mathew MaccumberHarvey$219K
- Rahul KomatiChicago$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.